Procaps Group, S.A Income from Continuous Operations 2020-2023 | PROCF

Procaps Group, S.A income from continuous operations from 2020 to 2023. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
Procaps Group, S.A Annual Income from Continuous Operations
(Millions of US $)
2022 $43
2021 $-101
2020 $-10
2020 $-13
2019 $-17
2019 $-0
2018 $-0
Procaps Group, S.A Quarterly Income from Continuous Operations
(Millions of US $)
2023-09-30 $8
2023-06-30 $27
2023-03-31 $7
2022-12-31 $10
2022-09-30 $23
2022-06-30 $-7
2022-03-31 $16
2021-12-31 $28
2021-09-30 $-111
2021-06-30 $-1
2021-03-31 $-17
2020-12-31 $-6
2020-09-30 $-1
2020-06-30 $-4
2020-03-31 $2
2019-12-31
2019-09-30
2019-06-30
2019-03-31 $-0
Sector Industry Market Cap Revenue
Medical MED-DRUGS $0.125B $0.410B
Procaps Group is a developer of pharmaceutical and nutraceutical solutions, medicines and hospital supplies. It develops, manufactures and markets over-the-counter and prescription drugs, nutritional supplements and high-potency clinical solutions. Procaps Group, formerly known as Union Acquisition Corp. II, is based in BARRANQUILLA, Colombia.
Stock Name Country Market Cap PE Ratio
NextEra Energy Partners, LP (XIFR) United States $0.828B 4.49